EHSI signs option with Regenevita for 'Neo Natal Progenitor Cell Expansion Technology'

Emerging Healthcare Solutions, Inc. (Pink Sheets:EHSI) announced today that the Company has signed an option with Regenevita, owner of the right to license Neo Natal Progenitor Cell Expansion Technology in Latin America. The core technology on which the Regenevita technology is based was originally developed by NASA, the National Aeronautics and Space Administration, and was sub-licensed to Regenevita for use with Neo Natal Progenitor Cell Expansion. The option begins a due diligence period for EHSI and also begins good faith negotiations between both parties with the intention of reaching a potential Sub-License Agreement. Regenevita (www.regenevita.com) is a subsidiary of Stematix, Inc. (www.stematix.com), and is a joint venture between Stematix and EDCO Ventures (www.edcoonline.org) with a goal to establish pioneering leadership in regenerative medicine for the Rio Grande / Rio Bravo Valley. Regenevita believes it has a unique, sustainable cellular banking model that can facilitate the widespread use of regenerative cell therapy.

“Our participation in this deal has the potential to reap generous rewards for our company in both revenue and technological advancements.”

"We are very impressed with the leadership and development team of Regenevita. It is our belief they have the ability to emerge as world leaders in the advancement of stem cell technology and research," stated Cindy Morrissey, President of EHSI. "Our participation in this deal has the potential to reap generous rewards for our company in both revenue and technological advancements."

Regenevita plans to initially establish two cellular banking operations: one in McAllen, Texas and the other in Reynosa, Mexico. The Reynosa bank will be located in the newest maternity hospital in Reynosa (opened in 2008) under a 50/50 joint venture with the Secretaria de Salud (Ministry of Health) of the Mexican State of Tamaulipas. The Regenevita facilities will initially bank umbilical cord blood from patient donations and for private families, and Regenevita plans to add capabilities and services to support regenerative medicine delivery in future years.

Emerging Healthcare Solutions focuses on the development of profitable emerging medical technology, a sector that also includes Amgen (NASDAQ: AMGN), Dendreon Corporation (NASDAQ: DNDN), Smith & Nephew Plc (NYSE: SNN) and Pharmaceutical Product Development (NASDAQ: PPDI).